$VTYX
Ventyx Biosciences, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022004442 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.338M $8.666M $133.0K
YoY Change 1166.96%
% of Gross Profit
Research & Development $17.41M $58.48M $1.307M
YoY Change -29.23% 818.65%
% of Gross Profit
Depreciation & Amortization $21.00K $30.00K $0.00
YoY Change 2000.0%
% of Gross Profit
Operating Expenses $22.75M $67.15M $1.440M
YoY Change -10.26% 852.44%
Operating Profit -$22.75M -$67.15M
YoY Change -10.26% 852.44%
Interest Expense $0.00 -$99.00K -$153.0K
YoY Change -72.35%
% of Operating Profit
Other Income/Expense, Net $15.00K -$16.60M -$15.11M
YoY Change -100.12% -21.42%
Pretax Income -$22.73M -$83.75M -$16.70M
YoY Change 197.25%
Income Tax
% Of Pretax Income
Net Earnings -$22.73M -$83.75M -$16.70M
YoY Change -39.61% 197.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$6.65
Diluted Earnings Per Share -$449.4K -$1.661M -$341.3K
COMMON SHARES
Basic Shares Outstanding 50.73M 12.83M
Diluted Shares Outstanding 50.59M 12.83M

Balance Sheet

Concept 2022 Q1 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $254.3M $258.6M $244.0K
YoY Change 105873.77%
Cash & Equivalents $41.69M $70.79M $244.0K
Short-Term Investments $212.7M $187.8M $0.00
Other Short-Term Assets $3.159M $4.444M
YoY Change 444300.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $257.5M $263.0M $245.0K
YoY Change 107255.1%
LONG-TERM ASSETS
Property, Plant & Equipment $275.0K $254.0K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $18.80M $28.15M
YoY Change
Other Assets $60.00K $60.00K
YoY Change
Total Long-Term Assets $20.45M $28.46M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $257.5M $263.0M $245.0K
Total Long-Term Assets $20.45M $28.46M $0.00
Total Assets $278.0M $291.5M $245.0K
YoY Change 118872.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.114M $4.661M $1.102M
YoY Change 322.96%
Accrued Expenses $10.40M $7.622M $301.0K
YoY Change 2432.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.79M $12.28M $1.403M
YoY Change 775.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.039M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $1.039M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.79M $12.28M $1.403M
Total Long-Term Liabilities $1.039M $0.00
Total Liabilities $18.83M $12.28M $30.90M
YoY Change -60.25%
SHAREHOLDERS EQUITY
Retained Earnings -$140.5M -$32.50M
YoY Change
Common Stock $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $259.1M $279.2M -$30.65M
YoY Change
Total Liabilities & Shareholders Equity $278.0M $291.5M $245.0K
YoY Change 118872.24%

Cashflow Statement

Concept 2022 Q1 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$22.73M -$83.75M -$16.70M
YoY Change -39.61% 197.25%
Depreciation, Depletion And Amortization $21.00K $30.00K $0.00
YoY Change 2000.0%
Cash From Operating Activities -$12.73M -$38.65M -$1.888M
YoY Change 321.53% 523.89%
INVESTING ACTIVITIES
Capital Expenditures $38.00K $262.0K $0.00
YoY Change
Acquisitions -$1.899M
YoY Change
Other Investing Activities -$16.47M -$214.1M $0.00
YoY Change
Cash From Investing Activities -$16.50M -$214.4M $0.00
YoY Change -969.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 86.00K 323.6M 2.080M
YoY Change -99.85% 5178.16%
NET CHANGE
Cash From Operating Activities -12.73M -38.65M -1.888M
Cash From Investing Activities -16.50M -214.4M 0.000
Cash From Financing Activities 86.00K 323.6M 2.080M
Net Change In Cash -29.10M 70.55M 192.0K
YoY Change -152.2% -108633.85%
FREE CASH FLOW
Cash From Operating Activities -$12.73M -$38.65M -$1.888M
Capital Expenditures $38.00K $262.0K $0.00
Free Cash Flow -$12.76M -$38.91M -$1.888M
YoY Change 528.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001851194
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10455
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40928
CY2021 dei Entity Registrant Name
EntityRegistrantName
Ventyx Biosciences, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2996852
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
662 Encinitas Blvd
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Encinitas
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92024
CY2021 dei City Area Code
CityAreaCode
760
CY2021 dei Local Phone Number
LocalPhoneNumber
593-4832
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
VTYX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
284800000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50729820
CY2020Q4 vtyx Convertible Safe Notes At Fair Value Related Party
ConvertibleSafeNotesAtFairValueRelatedParty
9727000
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70791000
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
244000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
187785000
CY2021Q4 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
29000
CY2020Q4 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
0
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4444000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
263020000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
245000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
254000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
28148000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
60000
CY2021Q4 us-gaap Assets
Assets
291482000
CY2020Q4 us-gaap Assets
Assets
245000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
238000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4661000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1102000
CY2021Q4 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
175000
CY2020Q4 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
17000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7622000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
301000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12283000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1403000
CY2020Q4 vtyx Change Of Control Derivative Liability Related Party
ChangeOfControlDerivativeLiabilityRelatedParty
16849000
CY2020Q4 vtyx Convertible Promissory Notes Related Party
ConvertiblePromissoryNotesRelatedParty
2920000
CY2021Q4 us-gaap Liabilities
Liabilities
12283000
CY2020Q4 us-gaap Liabilities
Liabilities
30899000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
47603832
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50526702
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2187187
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50408830
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2059157
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
397051000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6366000
CY2021 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
124000
CY2020 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
400000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28174000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-69000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1847000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117799000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32501000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-30654000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
291482000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
245000
CY2021 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
1234000
CY2020 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
965000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58481000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8666000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
684000
CY2021 us-gaap Operating Expenses
OperatingExpenses
67147000
CY2020 us-gaap Operating Expenses
OperatingExpenses
7050000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-67147000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-7050000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
27000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
99000
CY2020 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
358000
CY2021 vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-11051000
CY2020 vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-20765000
CY2021 vtyx Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-5476000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16599000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21124000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83746000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28174000
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1552000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85298000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28174000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83746000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83804000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28174000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.65
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.17
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12825598
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1988585
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-4128000
CY2020 vtyx Adjustments To Additional Paid In Capital Modification Of Debt Instruments With Related Party
AdjustmentsToAdditionalPaidInCapitalModificationOfDebtInstrumentsWithRelatedParty
1601000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
45000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28174000
CY2020 vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
0
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4386000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-38000
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-238000
CY2020 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
169000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2443000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
591000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-30654000
CY2021 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1735000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2733000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3058000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
224521000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2730000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-69000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83746000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
CY2021 us-gaap Profit Loss
ProfitLoss
-83746000
CY2020 us-gaap Profit Loss
ProfitLoss
-28174000
CY2021 us-gaap Depreciation
Depreciation
30000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2730000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
45000
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
99000
CY2020 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
358000
CY2021 vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-11051000
CY2020 vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-20765000
CY2021 vtyx Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-5476000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
21694000
CY2021 vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
-29000
CY2021 vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
158000
CY2020 vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
14000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5959000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
182000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38650000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6195000
CY2021 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-1899000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
232502000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
16500000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
262000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214365000
CY2021 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
164221000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
158815000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
450000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
6128000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
323551000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6130000
CY2021 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
11000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70547000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
244000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
309000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70791000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
244000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2020 vtyx Amendment To Convertible Promissory Notes Related Party
AmendmentToConvertiblePromissoryNotesRelatedParty
2706000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
224521000
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
38911000
CY2021 us-gaap Stock Issued1
StockIssued1
21260000
CY2021 vtyx Unrealized Gain Loss On Securities Non Cash
UnrealizedGainLossOnSecuritiesNonCash
-69000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117800000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
286700000
CY2021 vtyx Number Of Acquired Wholly Owned Subsidiaries
NumberOfAcquiredWhollyOwnedSubsidiaries
2
CY2021 vtyx Forward Stock Split And Reverse Stock Split Policy Policy Textblock
ForwardStockSplitAndReverseStockSplitPolicyPolicyTextblock
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">February 2021 Forward Stock Split and October 2021 Reverse Stock Split</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 26, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.933972</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for 1 forward stock split of its common stock.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, on October 11, 2021, the Company effected a 1 for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_52b701e3-21fa-4ff8-8d52-ca0e535a0f9d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.5644</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its capital stock.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The par value and the authorized shares of the capital stock were not adjusted as a result of the forward and reverse stock splits. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the forward and reverse stock splits for all periods presented.</span>
CY2021 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
On February 26, 2021, the Company effected a 7.933972 for 1 forward stock split of its common stock.
CY2021Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
7.933972
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Additionally, on October 11, 2021, the Company effected a 1 for 9.5644 reverse stock split of its capital stock.
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk. The Company purchases its available-for-sale marketable securities with financial institutions which management believes have high credit ratings. The Company performs periodic evaluations of the credit standing of the financial institutions for which it has marketable securities with.</span>
CY2021 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Derivative Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using a combination of probability analysis and Monte Carlo simulation or other acceptable valuation models. Derivative instruments are valued at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at the end of each reporting period.</span>
CY2021Q4 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4918000
CY2020Q4 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
234000
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 vtyx Fair Value Liabilities Level1 To Level2 To Level3 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2ToLevel3TransfersAmount
0
CY2020Q4 vtyx Fair Value Liabilities Level1 To Level2 To Level3 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2ToLevel3TransfersAmount
0
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
216002000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
86000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215933000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2529000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
CY2021Q4 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
175000
CY2020Q4 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
17000
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
21700000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7622000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
301000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
278000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
254000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
1899000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
599000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
16000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
7000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
802000
CY2021Q1 vtyx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
1576000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
143000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
143000
CY2021Q1 vtyx Business Combination Fair Value Of Shares Issued
BusinessCombinationFairValueOfSharesIssued
21032000
CY2021Q1 vtyx Business Combination Transaction Fees
BusinessCombinationTransactionFees
577000
CY2021Q1 vtyx Business Combination Fair Value Of Vested Common Stock Options Exchanged
BusinessCombinationFairValueOfVestedCommonStockOptionsExchanged
228000
CY2021Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
21837000
CY2021Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
21694000
CY2021 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
47603832
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of outstanding shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11113611
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2021Q2 vtyx Lessee Operating Lease Effective Start Date
LesseeOperatingLeaseEffectiveStartDate
2021-07-01
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q1 vtyx Lessee Operating Lease Effective Start Date
LesseeOperatingLeaseEffectiveStartDate
2021-07-01
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
CY2021Q1 vtyx Number Of Lab Room Lease
NumberOfLabRoomLease
2
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q3 vtyx Lessee Operating Lease Effective Start Date
LesseeOperatingLeaseEffectiveStartDate
2021-09-16
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1547753
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.20
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M3D
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
381000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
391000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
370000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
349000
CY2021Q4 vtyx Operating Leases Future Minimum Payments Due After Year Four
OperatingLeasesFutureMinimumPaymentsDueAfterYearFour
177000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1668000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2730000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
299000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4694554
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.70
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
197004
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.37
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34813
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.20
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6010490
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.83
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M7D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
78630000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6010490
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.83
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M7D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
78630000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1259642
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y2M8D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
23100000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-83746000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28174000
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1552000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85298000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28174000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12825598
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1988585
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.65
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.17
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6812322
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1675783
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 vtyx Effective Income Tax Rate Reconciliation Convertible Notes
EffectiveIncomeTaxRateReconciliationConvertibleNotes
-0.041
CY2020 vtyx Effective Income Tax Rate Reconciliation Convertible Notes
EffectiveIncomeTaxRateReconciliationConvertibleNotes
-0.158
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.054
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.107
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.052
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16541000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2307000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15362000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2307000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1179000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
The losses do not expire, but are limited to 80% utilization against taxable income.
CY2021 vtyx Operating Loss Carryforwards Limitations Taxable Income Percentage
OperatingLossCarryforwardsLimitationsTaxableIncomePercentage
0.80
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0000950170-22-004442-index-headers.html Edgar Link pending
0000950170-22-004442-index.html Edgar Link pending
0000950170-22-004442.txt Edgar Link pending
0000950170-22-004442-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img213036076_0.jpg Edgar Link pending
img213036076_1.jpg Edgar Link pending
img213036076_10.jpg Edgar Link pending
img213036076_11.jpg Edgar Link pending
img213036076_12.jpg Edgar Link pending
img213036076_13.jpg Edgar Link pending
img213036076_14.jpg Edgar Link pending
img213036076_15.jpg Edgar Link pending
img213036076_16.jpg Edgar Link pending
img213036076_2.jpg Edgar Link pending
img213036076_3.jpg Edgar Link pending
img213036076_4.jpg Edgar Link pending
img213036076_5.jpg Edgar Link pending
img213036076_6.jpg Edgar Link pending
img213036076_7.jpg Edgar Link pending
img213036076_8.jpg Edgar Link pending
img213036076_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtyx-20211231.htm Edgar Link pending
vtyx-20211231.xsd Edgar Link pending
vtyx-20211231_cal.xml Edgar Link unprocessable
vtyx-20211231_def.xml Edgar Link unprocessable
vtyx-20211231_htm.xml Edgar Link completed
vtyx-20211231_lab.xml Edgar Link unprocessable
vtyx-20211231_pre.xml Edgar Link unprocessable
vtyx-ex10_15.htm Edgar Link pending
vtyx-ex23_1.htm Edgar Link pending
vtyx-ex31_1.htm Edgar Link pending
vtyx-ex31_2.htm Edgar Link pending
vtyx-ex32_1.htm Edgar Link pending
vtyx-ex32_2.htm Edgar Link pending
vtyx-ex4_3.htm Edgar Link pending